Kornimate/medical-research-clean huggingface dataset:
effect of empagliflozin on ventricular repolarization.

Conditions: Diabetes Mellitus, Type 2; Coronary Heart Disease; Arrythmia, Cardiac

Summary: the present project aims to investigate if the empagliflozin has an antiarrhythmic action. analyzing the t-wave heterogeneity index, a new electrocardiographic risk marker associated with the prediction of cardiovascular risk, in diabetic patients and coronary artery disease, the investigators will verify if empagliflozin is associated with a reduction in electrical instability.

cardiovascular diseases are the leading cause of morbidity and mortality in diabetic patients. new hypoglycemic drugs are required to undergo cardiovascular safety studies for their release. in 2015, empa-reg outcome, which was done for empagliflozin´s approval was the first study to provide evidence that an antidiabetic agent could decrease cardiovascular events. the results demonstrated a reduction in the primary outcome (death by cardiovascular causes, nonfatal infarction, and nonfatal stroke), cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk who received empagliflozin in combination with standard treatment. it is noteworthy that the study population was under-optimized clinical treatment with antihypertensives, statin and aspirin and especially it is noteworthy that the difference in the primary outcome over placebo became evident only three months after treatment´s start. the potential mechanisms underlying the surprising cardiovascular benefits of empagliflozin are not fully understood. the present project aims to investigate if the empagliflozin has an antiarrhythmic action. analyzing the t-wave heterogeneity index, a new electrocardiographic risk marker associated with the prediction of cardiovascular risk, in diabetic patients and coronary artery disease, we will verify if empagliflozin is associated with a reduction in electrical instability.

Eligibility criteria:
inclusion criteria: * • age ≥ 18 years; * fasting glycemia\> 100 mg/dl or previous diagnosis of type 2 diabetes mellitus; * coronary artery disease, defined by one of the following criteria: the antecedent of myocardial infarction; the evidence of significant coronary stenosis in previous coronary angiography; the noninvasive positive test for ischemia (stress electrocardiogram, stress echocardiogram, stress scintigraphy) * twh ≥ 80 microvolts exclusion criteria: * chronic renal insufficiency with glomerular filtration rate ≤ 45 ml / min / 1.73m2; * hepatic insufficiency (determined by child-pugh, b or c classification); * age ≥ 85 years; * 12-lead resting electrocardiogram with the following changes: intraventricular conduction disorders (bundle branch block), pacemaker rhythm, atrial fibrillation or flutter, artifact stroke distortion or baseline fluctuation

Keywords: empagliflozin diabetes coronary heart disease
exercise-based pre-habilitation in bladder cancer patients prior to radical cystectomy: a feasibility study

Conditions: Bladder Cancer; Urothelial Carcinoma

Summary: the purpose of this study is to explore the feasibility and efficacy of a 12-week, home-based exercise program in bladder cancer patients undergoing curative intent neoadjuvant chemotherapy and rc.

the investigators will seek to recruit 20 patients diagnosed with muscle invasive localized urothelial carcinoma of the bladder who are scheduled to receive neo-adjuvant chemotherapy prior to rc from the queen elizabeth health sciences center in halifax, nova scotia. participants will be randomly allocated to standard of care treatment versus standard of care plus a multimodal, home-based program including strength and endurance exercises. outcomes measured will include feasibility data, patient outcomes, and post-surgical complications.

Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of localized muscle invasive urothelial carcinoma of the bladder (clinical stages ct2-4a, n0-1, m0); 2. treatment plan includes the administration of cisplatin-based systemic neoadjuvant chemotherapy prior to anticipated rc (typically four, 3-week cycles of cisplatin-based chemotherapy); 3. english fluency; 4. physician approval; and 5. participant willingness to participate in a 12-week, home-based exercise intervention. exclusion criteria: 1. unstable or symptomatic cardiac or pulmonary disease, musculoskeletal injury or co-morbid disease that precludes ability to exercise; and 2. significant cognitive limitations.

Keywords: bladder cancer urothelial carcinoma chemotherapy neoadjuvant exercise prehabilitation
clinical evaluation of the performance of bionet sphygmomanometer modules based on protocol presented by the international organization for standardization

Conditions: Blood Pressure

Summary: according to international standard (hereafter iso) blood pressure (bp) monitor clinical evaluation protocol (iso 81060-2:2018, non-invasive sphygmomanometers- part2: clinical investigation of intermittent automated measurement type) for bn1 (bnibp), an electronic sphygmomanometer module newly developed by bionet co., ltd., the clinical group and evaluation criteria presented in, the effectiveness of blood pressure measurement performance was evaluated. the auscultation method used as a reference (gold standard) of a non-invasive blood pressure (nibp) measurement method was used. the first blood pressure measurement was performed once each (reference bp not used for evaluation, r0; test bp not used for evaluation, t0) with auscultation and the test medical device (bm5 equipped with bn1 (bnibp)). the blood pressure used for evaluation was measured four times by auscultation (first reference bp to fourth reference bp, r1 to r4) and three times by the test medical device (first test bp to third test bp, t1 to t3) alternately. a minimum interval of 1 min was allowed between each blood pressure measurement. three data pairs (mean value of r1, r2 \& t1 / r2, mean value of r3 \& t2 / r3, mean value of r4 \& t3) were obtained from one study subject. this study aims to verify that the mean value of the differences and standard deviations of data pairs meet the criteria of iso 81060-2:2018.


Eligibility criteria:
inclusion criteria: * recruitment is made through the recruitment notice for patients and their guardians who visit hanyang university hospital. subjects who meet the criteria presented in iso 81060-2:2018 protocol 5.1 subject requirements are recruited. exclusion criteria: * emergency surgery patient * persons who have mental disorders such as mental retardation, autism, etc. and who have difficulty measuring blood pressure or are expected to have difficulties * a person who disagreed with the study

Keywords: hypotension hypertension prehypertension sphygmomanometers
blue light phototherapy

Conditions: Grover's Disease; Psoriasis Vulgaris

Summary: this study will use blue-light photo-therapy to treat patients with psoriasis vulgaris and grover's disease.


Eligibility criteria:
inclusion criteria: 1. patient's aged 18-89 at time of enrollment 2. previous diagnosis of psoriasis vulgaris or grover's disease exclusion criteria: 1. all groups: subjects who are younger than 18 years of age or older than 90 years of age 2. patients who have received topical or systemic treatment within the prior 2 weeks of planned phototherapy 3. patients prescribed any of the following drugs for issues not related to their psoriasis or grover's disease * topical steroids * calcineurin inhibitors * methotrexate * retinoids * biologic agents 4. unable to schedule phototherapy sessions 5. we will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.
flowtriever pulmonary embolectomy clinical study

Conditions: Pulmonary Embolism; Acute Pulmonary Embolism; Submassive Pulmonary Embolism; Massive Pulmonary Embolism

Summary: evaluate the safety and effectiveness of the flowtriever system for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism.


Eligibility criteria:
inclusion criteria: * clinical signs, symptoms and presentation consistent with acute pe * pe symptom duration ≤ 14 days * cta evidence of proximal pe * rv/lv ratio ≥ 0.9 without syncope * systolic bp ≥ 90 mmhg * stable heart rate \<130 bpm prior to procedure * patient deemed medically eligible for interventional procedure(s), per institutional guidelines and/or clinical judgment exclusion criteria: * thrombolytic use within 30 days of baseline cta * pulmonary hypertension with peak pap \> 70 mmhg by right heart catheterization * vasopressor requirement after fluids to keep pressure ≥ 90 mm hg * fio2 requirement \> 40% or \> 6 lpm to keep oxygen saturation \> 90% * hematocrit \< 28% within 6 hours of index procedure * platelets \< 100,000/µl * serum creatinine \> 1.8 mg/dl * inr \> 3 * major trauma iss \> 15 * presence of intracardiac lead in right ventricle or atrium placed within 6 months * cardiovascular or pulmonary surgery within last 7 days * actively progressing cancer * known bleeding diathesis or coagulation disorder * left bundle branch block * history of severe or chronic pulmonary arterial hypertension * history of chronic left heart disease with left ventricular ejection fraction ≤ 30% * history of uncompensated heart failure * history of underlying lung disease that is oxygen-dependent * history of chest irradiation * history of heparin-induced thrombocytopenia * any contraindication to systemic or therapeutic doses of heparin or anticoagulants * known anaphylactic reaction to radiographic contrast agents that cannot be pretreated * imaging evidence or other evidence that suggests the subject is not appropriate for mechanical thrombectomy intervention * life expectancy of \< 90 days * female who is pregnant or nursing * current participation in another investigational drug or device treatment study

Keywords: thromboembolism thrombectomy right heart strain submassive pe right ventricle dysfunction massive pe
radiofrequency in differentiated thyroid cancer metastatic lymph node: prospective study of safety and efficacy

Conditions: Differentiated Thyroid Cancer

Summary: radiofrequency (rf) could be technically feasible and effective in the treatment of lymph node metastases of differentiated thyroid cancer. it could constitute a minimally invasive and feasible therapeutic alternative in ambulatory, allowing a reduction of the tumoral volume sufficient to limit the symptoms even to induce a tumor remission, a normalization of the tumoral markers and a better quality of life. the aim of this study is to evaluate the anti-tumor echographic efficacy at 12 months of radiofrequency on lymph node (ln) metastasis of thyroid cancer


Eligibility criteria:
inclusion criteria: * patients over age of 18 years * with differentiated thyroid cancer (papillary, follicular) histologically confirmed, and absence of anaplastic component * previous treatment by total thyroidectomy and cervical lymph node dissection. * previous treatment by at least 1 therapeutic radioactive iodine (minimum activity 740mbq) * persistence on cervical ultrasound of at least 1 cervical metastatic lymph node, visible at ultrasound, small diameter between ≥10 mm and ≤30mm, volume maximum 20ml, spotted on a picture, and confirmed by cyto-punction * signed informed consent exclusion criteria: * location of ln metastasis with significant risk of local complication (nervous, vascular) according baseline ultrasound assessment * patient carrier of a pacemaker or a defibrillator * congenital or acquired hemostasis abnormality, anticoagulant therapy or double platelet antiaggregatory (aspirin and clopidogrel) * hypersensitivity to local anesthetic * poor general condition (performance status eastern cooperative oncology group (ecog) \> 1) * survival estimated less than 12 months * patient who can't follow the instructions of rf therapy or who can't be followed during 2 years in order to meet the objectives of the study * non affiliation to a social security * pregnant or breast feeding women at the time of rf * beta hormone chorionic gonadotrope (hcg) positive test (pregnancy) before rf therapy * baseline cervical ultrasound, by expert operator trained to rf, not fulfilling feasibility criteria for rf realisation because of the location of ln metastasis or the way to reach it * controlateral recurrent palsy on nasofibroscopy

Keywords: differentiated thyroid cancer radiofrequency
restorative treatment in first molars affected by molar-incisor hypomineralization

Conditions: Molar Incisor Hypomineralization

Summary: the restorative management of molars with molar-incisor hypomineralization (mih) represents a challenge in the clinical practice with high failure rate. thus, this clinical trial aimed to evaluate the clinical survival of direct composite resin restorations in first permanent molars (fpms) that are affected by mih, comparing two adhesive systems.

for the research, it was selected first permanent molars (fpms) with mih from children aged 6-8 years. fpm fully erupted and with restorative treatment needed was the inclusion criteria. we excluded fpms with destroyed crowns. the fpms were randomly assigned to two groups: g1 (self-etching adhesive) and g2 (total-etching adhesive). clinical evaluation was performed during 18 months according to the usphs-modified by a blinded examiner. the actuarial method was used to evaluate survival of the restorations and fisher's exact test was used to compare differences between the groups (α=5%).

Eligibility criteria:
inclusion criteria: * children and/or parents who agree in participate of the study * children were born and living in araraquara, sp, brazil * presence of the first permanent molars totally erupted with defects classified as enamel post eruptive breakdown (peb) or unsatisfactory atypical restoration (uatr), with or without carious lesions. exclusion criteria: * children and/or parents who do not agree in participate of the study * first permanent molars with enamel malformation associated with syndromes, * dental fluorosis, * first permanent molars with destroyed crowns, * imperfect amelogenesis * fixed orthodontic appliances.
the effects of hamstring stretching with and without neural load on flexibility, maximum isometric strength and tibial nerve pressure pain threshold

Conditions: Healthy

Summary: the study will be carried out at the faculty of nursing and physiotherapy of the university of alcala. the study has been approved by the animal research and experimentation ethics committee of the university of alcalá. healthy subjects will be recruited and divided into two groups randomly to perform a hamstring stretching program for two months. one group will perform a stretch with neural load and the other without neural load, although both groups will stretch for the same amount of time, repetitions and subjective sensation. participants will be measured before and after performing their assigned stretch. then, a new post-stretch measurement will be taken after two months, period during which the subjects will perform the stretching program on their own. finally, subjects will be asked to quit the stretching program to take a final evaluation measurement after one month of follow-up. the objective will be to evaluate the effects of stretching with and without neural load on hamstring flexibility (main variable), maximum isometric strength and tibial nerve pressure pain threshold.


Eligibility criteria:
inclusion criteria: * healthy subjects who do not perform hamstring stretches with neural load in their daily training routine exclusion criteria: * elite athletes competing or preparing for competition * lower limb surgery * hamstring injury in the last year * neurological, rheumatologic and/or orthopedic pathological history of lower limbs. * other comorbidities
exercise and physical activity in children with pediatric acquired brain injury

Conditions: Acquired Brain Injury

Summary: exercise and physical activity in children with pediatric acquired brain injury

although emerging approaches have emerged in the design of interventions that promote an orientation towards physical activity scientific evidence on their efficacy in this particular population remains limited. this underscores the need for further research to evaluate the efficacy of these intervention approaches in the context of pediatric abi.

Eligibility criteria:
inclusion criteria: * be under 18 years of age and present a medical diagnosis of pediatric acquired brain injury. * have the informed consent completed and signed * present a state that allows following indications for the practice of exercise and physical-sports activity. exclusion criteria: * have medical comorbidities that contraindicate the safe performance of the program (i.e., cardiac or respiratory instability, uncontrolled seizures). * have additional disabling conditions, such as cognitive impairment and/or an inability to communicate with the researcher verbally, in writing, or through an emissary. * non-attendance and/or non-collaboration at 70% of the sessions of the program.

Keywords: pediatric acquired brain injury exercise physical-sports activity intervention
treatment of chronic lymphocytic leukemia

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Summary: cll is a disease of the elderly, identifying effective therapies with better toxicity profiles is thus a high priority, and targeted therapies may allow attainment of this goal.

chronic lymphocytic leukemia (cll) is a common adult leukemia characterized by the extensive accumulation of monoclonal, relatively mature cd5+cd23+ b lymphocytes in lymphoid organs, bone marrow, and peripheral blood. cll cells accumulate because of defective apoptosis, which extends survival. cll is a heterogeneous disease. chemoimmunotherapy is the standard front-line approach for patients younger than 65 years with cll, with the combination of fludarabine, cyclophosphamide, and rituximab used most commonly. some cll patients do not respond well to routine chemoimmunotherapy. despite recent advances in the treatment of cll by use of modern chemoimmunotherapy, the disease remains incurable for most patients with the exception of those who have the option of an allogeneic transplantation. however, treatments with chemoimmunotherapy are associated with significant toxicities and sustained immunosuppression, and the rates of myelosuppression and infection are high. such complications are more frequent and more severe in patients older than 65 years because of reduced marrow reserve, and presence of comorbidities. because cll is a disease of the elderly, identifying effective therapies with better toxicity profiles is thus a high priority, and targeted therapies may allow attainment of this goal. cll tumor cells are highly dependent on the microenvironment where cytokines (eg, cd40l, baff, il-4, il-6), and contact (eg, stromal cells) promote cell activation and proliferation, and also resistance to spontaneous and drug-mediated apoptosis. many of these microenvironment-activated pathways merge with tsps exported by xpo1. xpo1 is therefore a highly attractive molecular target to explore in cll, because it impacts multiple antitumor and growth suppressive signaling pathways that are dysregulated in this disease. the investigators therefore hypothesized that a selective xpo1 inhibitor would show efficacy with an acceptable therapeutic index in cll and other diseases. indeed, xpo1 inhibition in normal cells (ie, possessing an intact genome) leads to transient cell cycle arrest without cytotoxicity, followed by fast recovery after the drug is removed. to date, efforts to clinically pharmacologically inhibit xpo1 have been unsuccessful because of off-target effects. a selective xpo1 antagonist may allow targeting of the tsps axes in tumor cells.

Eligibility criteria:
inclusion criteria: * patients with cll

Keywords: chronic lymphocytic leukemia xpo1 in vitro in vivo
early intervention for erectile dysfunction after laparoscopic resection for rectal cancer

Conditions: Rectal Tumors; Erectile Dysfunction

Summary: although the high prevalence of erectile dysfunction (ed) was detected among male patients after the treatment for colorectal cancer, published reports depicting the erectile dysfunction experience of patients with colorectal cancer ot underpin service development are insufficient. furthermore,unlike patients with prostate cancer, men with colorectal cancer are not routinely offered information and treatment for erectile dysfunction.however, investigations on patients after surgery for prostate cancer could provide some potentially useful insights. the ability of sildenafil and vacuum erection device (ved) to aid in the return of erections after nerve-sparing radical prostatectomy has been established, which may benefit rectal cancer patients after surgery with ed. laparoscopic surgery, although technically demanding and associated with a long learning curve, has the advantage of clear visualization for the smallest structures,including the autonomic nerves. laparoscopic resection for rectal cancer could thus facilitate preservation of the pelvic autonomic nerves. this study aimed to identify whether early intervention is effective at reducing the rate of ed at 12 months.


Eligibility criteria:
inclusion criteria: 1. 18 \< age \< 70 2. sexually active men without the consistent use of erectile aids pre-operatively 3. rectal cancer confirmed by histology 4. undergoing a bilateral nerve sparing laparoscopic rectal resection 5. iief-5 domain score \> =20 before surgery 6. presence of a female sexual partner 7. willingness to participate in clinical research as evidenced by their signature on the informed consent form exclusion criteria: 1. has a history of cardiac failure, angina, or life-threatening arrhythmia within the past 6 months 2. has taken or has been prescribed nitrate medication in any form in the last 6 months 3. contraindication to sildenafil (e.g. nitrates, hypersensitivity) 4. contraindication to vacuum erection device (e.g. coagulation abnormality, stick cell disease) 5. men with a history of known penile deformity or peyronie's disease 6. pre or postoperative androgen therapy

Keywords: erectile dysfunction laparoscopic surgery rectal cancer sildenafil vacuum erection device
flax lignans and heart health

Conditions: Hypercholesterolemia

Summary: purpose: to demonstrate the efficacy of beneflax™ flaxseed lignan (sdg) concentrate to lower serum cholesterol levels. background: flaxseed has been studied for various health benefits in humans, including prostate health, glucose control, and cardiovascular health. cholesterol levels and high blood pressure are known to be risk factors for cardiovascular disease. whole flaxseed has had variable effects on serum lipid levels, perhaps a consequence of variations in the amounts of secoisolariciresinol diglucoside (sdg) found in different flax cultivars, making the study of this bioactive compound difficult. hypothesis: flaxseed lignan (sdg) extract (beneflax) significantly lowers total and ldl cholesterol. flaxseed lignans also lower blood pressure and fasting glucose levels.


Eligibility criteria:
inclusion criteria: * men, 40-65 yrs/old, postmenopausal women 50-65 yrs/old not \> 5 yrs post menopause. all subjects were hypercholesterolemic with either total cholesterol \>240 mg/dl and \ 140 mg/dl and \<190 mg/dl at the screening visit. exclusion criteria: * excluded subjects included diabetics, people being actively treated with niacins, fibrates, statins, insulin, ace inhibitors or other cholesterol/ blood pressure pharmaceutical treatments, people who consumed large amounts of soy, flax, rye breads, pumpkin seeds, hydrolyzed milk products, sterols, and/or berries (strawberries/blueberries) or supplements aimed at cholesterol reduction such as spruce lignans, sytrinol (poly methoxylated flavanols), polycosinols, people consuming flaxseed on a regular basis.

Keywords: hypercholesterolemia postmenopause secoisolariciresinol diglucoside flaxseed lignans enterolactone enterodiol serum cholesterol ldl cholesterol